CAM
AYTU icon

Crown Advisors Management’s AYTU BioPharma AYTU Stock Holding History

Crown Advisors Management’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Buy
200,000
+55,000
+38% +$130K 0.24% 42
2026
Q1 		$395K Buy
+145,000
New +$371K 0.26% 38

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Crown Advisors Management's AYTU Position: Q2 2026 in Review

Crown Advisors Management increased its AYTU BioPharma (AYTU) stake by 38% in Q2 2026, buying an estimated $130K and bringing the position to 200,000 shares worth $430K. The position accounts for 0.24% of the portfolio, ranked #42.

Crown Advisors Management first reported a position in AYTU in Q1 2026 and has held it in 2 quarters since. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

  • Crown Advisors Management held 200,000 shares of AYTU BioPharma worth $430K as of Q2 2026.
  • Crown Advisors Management bought 55,000 AYTU BioPharma shares in Q2 2026, an estimated $130K.
  • AYTU BioPharma made up 0.24% of Crown Advisors Management's portfolio in Q2 2026, its #42 holding.
  • Crown Advisors Management first reported a position in AYTU BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Crown Advisors Management's 13F filing for Q2 2026, filed 7 Aug 2026.